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H19 lncRNA alters methylation and expression ofHnf4α
in the liver of metformin-exposed fetuses
Jie Deng1,6, Martin Mueller1,2,6, Tingting Geng1,3, Yuanyuan Shen1,4, Ya Liu1,5, Peng Hou3, Ramanaiah Ramillapalli1, Hugh S Taylor1,
Michael Paidas2 and Yingqun Huang*,1
Metformin is the most widely used anti-diabetic medication worldwide. However, human and animal studies suggest that prenatal
metformin exposure may increase the risk of metabolic disorders in adult offspring, yet the underpinning mechanism remains
unclear. Here we report that metformin-exposed mouse fetuses exhibit elevated expression of the H19 long noncoding RNA, which
induces hypomethylation and increased expression of hepatocyte nuclear factor 4α (HNF4α). As a transcription factor essential
for morphological and functional differentiation of hepatocytes, HNF4α also has an indispensable role in the regulation of
expression of gluconeogenic genes. Consistently, H19 overexpression in a human liver cell line leads to decreased methylation
and increased expression of Hnf4α, with concomitant activation of the gluconeogenic program. Mechanistically, we show that the
methylation change of Hnf4α is induced by H19-mediated regulation of S-adenosylhomocysteine hydrolase. We also provide
evidence that altered H19 expression is a direct effect of metformin in the fetal liver. Our results suggest that metformin from the
mother can directly act upon the fetal liver to modify Hnf4α expression, a key factor for both liver development and function, and
that perturbation of this H19/Hnf4α-mediated pathway may contribute to the fetal origin of adult metabolic abnormalities.
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A hallmark of type 2 diabetes (T2D) and gestational diabetes
mellitus (GDM) is hyperglycemia and insulin resistance.
Polycystic ovary syndrome (PCOS) is another common
endocrine disorder among women of reproductive age. PCOS
causes anovulation and infertility, and is often associated with
obesity and insulin resistance. Pregnant women with PCOS,
GDM, or nondiabetic obesity have a significantly higher risk
of adverse pregnancy and infant outcomes, including mis-
carriages, preeclampsia, fetal macrosomia, preterm birth, and
high infant morbidity and mortality.1 Metformin is an oral
biguanide agent that has been widely prescribed for the
treatment of T2D. In the past decade, metformin has been
used extensively in the treatment of PCOS and GDM,1 and
recently in nondiabetic obese pregnant women.2,3 Metformin
freely crosses the placental barrier, reaching fetal concentra-
tions of more than 50% of those detected in the maternal
circulation.4,5 Therefore, metformin administration during
pregnancy has the potential of both direct and indirect (through
altering the maternal environment) impact on the fetus.
Interestingly, in a follow-up study of a randomized, controlled
trial on PCOS women, the authors reported significantly
higher fasting glucose in 8-year-old children born to women
treated with metformin compared to placebo from first
trimester until delivery.6 Likewise, when female mice on
regular diet were exposed to metformin throughout pregnancy
(despite no significant change in bodyweight), the offspring
(both male and female) had a decreased bodyweight at
embryonic day 18.5 (E18.5) but gained more weight and
mesenteric fat in adult when challenged with high-fat diets
(HFD). Notably, the offspring also had enlarged livers despite
little changes in the lipid profile. Moreover, the male adult
offspring additionally developed elevated fasting glucose and
glucose intolerance.5 While the molecular mechanism under-
lying these observations remains to be investigated, the
results raise the concern that in uterometformin exposuremay
alter fetal liver development and function, setting the stage for
long-term consequences on metabolism in adult life.
One well-studied example of prenatal events that lead to
long-term metabolic problems is dexamethasone exposure
during the last week of gestation, which causes low birth-
weight and hyperglycemia and glucose intolerance in adult
rats7 and sheep.8 In rats, a positive correlation between
dexamethasone exposure and an elevated expression of
hepatocyte nuclear factor 4α (HNF4α), together with its
regulated phosphoenolpyruvate carboxykinase 2 (PEPCK,
encoded by pck1/pck2) was identified in the fetal liver.9 Hnf4α
encodes a transcription factor essential for hepatocyte
differentiation and maturation, both morphologically and
functionally. It also acts to regulate expression of key
gluconeogenic genes, including Pck1 and glucose-6-
phosphatase (G6pc).10,11 Both Pck1 and G6pc encode rate-
controlling enzymes that catalyze the first and last steps of
gluconeogenesis reaction, respectively.12 HNF4α binds to
well-characterized cis-elements on the promoters of Pck1 and
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G6pc, thereby activating transcription.10,13 As hepatic gluco-
neogenesis normally does not occur at a considerable level
until after birth, the apparently premature activation of
gluconeogenesis program may contribute to the adverse
consequences on glucose metabolism in adulthood.
The developmentally regulated imprinted H19, together
with its co-regulated Igf2, has an important role in embryo
development and growth control. H19 is abundantly
expressed in the placenta and fetal tissues and strongly
downregulated postnatally, except in a few adult tissues,
including skeletal muscle and heart.14 H19 encodes a multi-
functional long noncoding RNA (herein called H19) and has
been shown to influence DNA methylation in a genome-wide
manner through interaction with S-adenosylhomocysteine
hydrolase (SAHH).15,16 SAHH is the only eukaryotic enzyme
that hydrolyzes S-adenosylhomocysteine (SAH), a potent
product inhibitor of SAM-dependent methyltransferases,
including DNA methyltransferases. H19 binds to SAHH and
inhibits its enzymatic activity. This causes accumulation of
SAH and inhibition of DNA methyltransferases, leading to
decreased DNA methylation.15,16 H19 expression is normally
negligible in adult liver, but an elevated expression was noted
in human patients with T2D.17 Given that excessive hepatic
gluconeogenesis contributes significantly to the hyperglyce-
mia in T2D,12 we hypothesized that H19 may have a role in
gluconeogenesis regulation.
In the present work, we identify altered expression of Hnf4α
in the liver of prenatally metformin-exposed fetuses. We
provide evidence that metformin from the mother can directly
act upon the fetal liver to upregulate H19, which in turn induces
changes in Hnf4α expression via an epigenetic mechanism.
Given that HNF4α is an essential factor both for liver
development and function, our results provide a potential
mechanistic insight linking prenatal metformin exposure to
adult metabolic disorders.
Results
Metformin-exposed fetuses have a decreased body-
weight. Pregnant mice on regular diet were given metformin
(or vehicle) orally at a daily dose of 250 mg/kg from
embryonic day 0.5 (E0.5) through E18. Fetuses were
collected at E18.5. The metformin dosage was chosen based
on published studies from the mouse.5,18,19 This dosage was
well tolerated, elicited no recognizable toxicity, and had no
significant effects on maternal bodyweight and litter size
across different mouse strains (including CD-1 used in the
current study).5,18,19 Further, this dosage was equivalent to
that used in the studies of pregnant women with PCOS and
nondiabetic obesity.2,3,6,20,21 It produced metformin concen-
trations in the maternal and fetal circulation in mice similar to
those measured in PCOS women.5,21
Metformin treatment did not alter maternal blood glucose
levels (Figure 1a), consistent with previous reports showing no
blood glucose-lowering effect of metformin on regular-diet-fed,
nondiabetic pregnant mice.19 Nor were there significant
changes in the litter size (Figure 1b) and viability (data not
shown). However, metformin-treated dams produced fetuses
with a slightly but significantly lower bodyweight at E18.5
(Figure 1c). This is in line with a published report that
gestational metformin-exposed mouse fetuses had a reduced
bodyweight at E18.5.5 Notably, new born rats prenatally
exposed to dexamethasone had a decreased birthweight and
also developed hyperglycemia and glucose intolerance in
adulthood.7 In humans, low birthweight (including those within
the normal range, not just severely underweighted babies) is a
strong predictor of insulin resistance and diabetes in adult
life.22-24 Together, our results suggest that low bodyweight
may predispose metformin-exposed fetuses to developing
metabolic abnormalities in adult life.
Metformin-exposed fetuses display altered hepatic gene
expression. Evidence from both human and animal studies
suggests that gestational metformin exposure has a deleter-
ious effect on glucose metabolism in adulthood.5,6 To begin to
elucidate the molecular mechanism that might link prenatal
metformin exposure to adult metabolic defects, we examined
expression of a subset of genes in control and metformin-
exposed fetal livers. The control and metformin group
consisted of five and seven pregnant dams, respectively.
Livers from one fetus per dam, selected at random, were used
for analysis. RNAs were isolated from the livers and gene
expression was determined by reverse transcription and
quantitative real-time PCR (RT-qPCR) analysis. The
metformin-exposed fetuses had a significantly increased
expression of H19, Hnf4α, and G6pc, compared to the control
group (Figures 2a–c), while the expression of both Pck1 and
Pck2 were unaltered (Figures 2d and e). Interestingly, the
Figure 1 Gestational metformin exposure reduces fetal bodyweight. (a) Maternal blood glucose on gestational day 18.5 showing no significant difference between the groups.
Control group, n (dams)= 5; metformin group, n (dams)= 7. NS, not statistically significant. (b) Scatter plots of litter size, with each dot representing a dam. The horizontal line
depicts group median and the whiskers mark the interquartile range. (c) Scatter plots of fetal bodyweight at E18.5, with each dot represents a fetus. Control group, n (fetuses from
5 dams)= 48; metformin group, n (fetuses from 7 dams)= 63. P-value indicates statistically significant
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insulin receptor INSR was downregulated in the metformin
group (Figure 2f). Importantly, Spearman correlation revealed
a strong positive relationship between H19 and Hnf4α
(P=0.0003; Figure 2g), suggesting an in vivo functional
interplay between the two genes (see below). There was also
a borderline significant correlation between H19 and G6pc
(P=0.0556; Figure 2h). This was not surprising given that
G6pc is further downstream of the regulatory axis as
compared to Hnf4α.10,11 There was no significant difference
in the expression of Igf2 between the two groups (Figure 2i),
despite that H19 and Igf2 were previously reported to be co-
regulated in mouse skeletal muscle during development.14
Thus, gestational metformin exposure causes altered hepatic
expression of H19 and Hnf4α, together with its regulated key
gluconeogenic gene G6pc, as well as insulin signaling
pathway gene Insr in the fetus.
H19 upregulates Hnf4α expression and glucose produc-
tion in hepatic cells. In light of a previous report on H19
increase in T2D patient livers17 and our own observation from
human endometrial cancer cells that downregulation of H19
correlated with increased promoter methylation of Hnf4α
(Supplementary Data S1 in ref. 16), we wanted to test
whether H19 might regulate Hnf4α in the fetal liver. H19
expression is robust in fetal hepatocytes but is sharply
repressed in fully differentiated hepatocytes after birth.25
However, H19 expression is reactivated in hepatocellular
carcinoma.26 Thus, we used Huh7 human hepatocellular
carcinoma cells as an in vitro model system for our studies,
because they mimic fetal hepatocytes in terms of H19
expression. To address whether increased H19 expression
would upregulate Hnf4α, Huh7 cells were transfected with a
human H19 expression plasmid (pH19)27 or control empty
vector (Vec), followed by RNA and protein analysis. H19
overexpression increased expression of Hnf4α, together with
its regulated genes G6pc and Pck1 at both the mRNA
(Figure 3a) and protein (Figure 3b) levels. H19 overexpres-
sion also enhanced glucose production (Figure 3c). These
results suggest that H19 has a causative role in increasing
Hnf4α expression and gluconeogenesis in hepatic cells.
Figure 2 Gene expression in fetal livers. (a–f and i) Scatter plots of RNA levels assessed by RT-qPCR. Control group, n (fetuses from 5 dams)= 5; metformin group,
n (fetuses from 7 dams)= 7. P-values are indicated. (g and h) Spearman correlation suggests an in vivo positive relationship between the expressions of H19, Hnf4α, and G6pc.
Spearman correlation coefficient, P-value, and sample numbers are marked on the left top of the plot
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Metformin upregulates H19 in hepatic cells. As metformin
can cross the placenta to reach the fetus, gestational
metformin exposure could potentially affect gene expression
of the pregnant dams, the placenta, and the fetus. Thus, the
mechanisms underlying gene expression changes in the
fetus are likely complex, reflecting both direct and indirect
(through modification of maternal and placental functions)
effects of metformin. To determine whether the altered
expression of H19 might be a direct impact of metformin on
the fetal liver, we incubated Huh7 cells with metformin and
found that it increased H19 expression in a dose-dependent
manner (Figure 3d). Importantly, the metformin doses used
were within the therapeutic concentration range found in the
plasma of T2D human patients.28 Taken together, we propose
that the upregulation of H19 in the fetal liver is likely a direct
effect of metformin on the fetus.
Hnf4α is hypomethylated in liver of metformin-exposed
fetuses. Our previous genome-scale methylation studies
from human endometrial cancer cells revealed a correlation
between decreased H19 expression and increased methyla-
tion at multiple CpG sites within a highly conserved promoter
region of human Hnf4α (Figure 4a) (Supplementary Data S1
in ref. 16). This suggested to us that H19 may regulate Hnf4α
expression by affecting methylation of this differentially
methylated region (DMR), given that H19 acts to alter DNA
methylation genome-wide through interaction with SAHH.15
To test this possibility, we transfected Huh7 cells with pH19 or
Vec and asked whether increased H19 expression would
lead to hypomethylation of the DMR. We compared methyla-
tion between control and H19-overexpressed cells by
quantitative methylation-specific PCR (QMSP) using a well-
established method.15 We observed decreased methylation
of the DMR in H19-overexpressed versus control cells
(Figure 4b, compare second column to first column on the
left). As H19 acts to inactivate SAHH, thereby decreasing
gene methylation,15,16 incubation of Huh7 cells with D-
Eritadenine (DEA), a pharmacological inhibitor of SAHH,
produced an effect similar to that of H19 overexpression
(Figure 4b, compare third column to first column). This
suggests that H19 regulates Hnf4α promoter methylation via
the previously identified H19/SAHH pathway. As decreased
promoter methylation in general activates gene expression,
we observed increased expression of Hnf4α in both pH19-
transfected and DEA-treated cells (Figure 4c). Together,
these results suggest that H19 regulates promoter methyla-
tion and expression of Hnf4α in hepatic cells.
To determine whether this regulation also occurs in vivo,
QMSPanalysis was performed on genomic DNA isolated from
livers of mouse fetuses with or without metformin exposure.
On the basis of the results from Huh7 cells, we predicted
hypomethylation of Hnf4α in metformin-exposed as compared
to control livers. The three differentially methylated CpG sites
(red highlighted, Figure 4a) in the conserved promoter region
of mouse Hnf4α was identified by genome-wide methylation
profiling (results to be published elsewhere). As shown in
Figure 4d, there was clearly a decrease in Hnf4α promoter
methylation in the liver of metformin-exposed versus control
Figure 3 H19 overexpression and metformin treatment in Huh7 cells. (a and b) Huh7 cells were transfected with Vec or pH19. RNA (a) and protein (b) were isolated at 24 and
48 h post transfection, respectively, and levels were determined. In (b), representative gel images from three independent western blot experiments are shown, with fold increase
in pH19-transfected compared to Vec-transfected cells marked on the right. Numbers are mean± S.D. (n= 3). **Po0.01. The molecular weights of the proteins are indicated on
the left. (c) Huh7 cells were transfected with Vec or pH19. Glucose output assays were carried out at 48 h post transfection. Numbers are mean± S.D. (n= 3). **Po0.01. (d)
Huh7 cells were treated with metformin at the indicated concentrations for 48 h. RT-qPCR results show increased expression of H19 in a dose-dependent manner. Numbers are
mean± S.D. (n= 3). P-values are indicated
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fetuses. The negative correlation between H19 expression
and Hnf4α methylation (Figure 4e) further supports an in vivo
regulation of Hnf4α methylation by H19. Collectively, these
results suggest that increased Hnf4α expression is likely a
result of decreased Hnf4α methylation, which is caused by an
elevated expression of H19 by metformin in the fetal liver.
Discussion
We show that in the mouse, metformin exposure through-
out gestation reduces fetal bodyweight. It also downregulates
Insr and upregulates H19 in the fetal liver, which induces
hypomethylation and expression of Hnf4α, with subsequent
activation of gluconeogenic genes. We also show that the
Figure 4 H19 regulates Hnf4αmethylation in vitro and in vivo. (a) Sequences of DMRs in the conserved promoter region of human and mouse Hnf4α. The three differentially
methylated cytosine residues are highlighted in red. The numbers on top of the sequences mark the positions of the indicated nucleotides in the chromosomes. (b) Huh7 cells
were transfected with Vec, pH19, or Vec plus DEA. Genomic DNAs were extracted 15 h later and analyzed by QMSP. Numbers are mean± S.D. (n= 3). **Po0.01. NS, not
statistically significant. (c) Huh7 cells were treated as described in b. RNAs were extracted 24 h later and analyzed by RT-qPCR. Numbers are mean±S.D. (n= 3). **Po0.01.
NS, not statistically significant. (d) Scatter plot of Hnf4α methylation in mouse fetal livers. Control group, n (fetuses from 5 dams)= 5; metformin group, n (fetuses from 7
dams)= 7. (e) Spearman correlation between H19 RNA level and Hnf4α promoter methylation, showing a negative correlation
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H19-induced alteration of methylation in a conserved promoter
region of Hnf4α is SAHH-dependent. We provide evidence
that the H19 expression change is likely a direct effect of
metformin on the fetal liver.
We believe that we have identified a potentially novel
mechanism linking prenatal metformin exposure to adult onset
of metabolic disorders in the mouse, which may have an
important clinical implication for human patients. As the fetus
has a continuous glucose supply from the mother in utero,
hepatic gluconeogenesis normally is not activated until after
birth. This has been attributed primarily to the low expression
of rate-limiting gluconeogenic enzymes such as G6PC and
PEPCK, and their regulatory transcriptional factors, including
HNF4α.29,30 However, premature activation of the gluconeo-
genic pathway, especially an increase in expression of Hnf4α
andPck1/Pck2, in fetuses exposed in utero to dexamethasone
or to maternal HFD, has been associated with adulthood
diabetic symptoms in both rodents and monkeys.9,31,32 This
suggests that gluconeogenic gene activation before birth may
be a common underlying mechanism for fetal programming of
adult metabolic diseases. Indeed, a significant induction of
Hnf4α has been seen in all three cases: gestational exposure
to metformin (this report); to dexamethasone;9 or to maternal
HFD.31 While previous studies reported an increase in
expression of Pck1 in maternal HFD31,32 or Pck29 in
dexamethasone-9 exposed fetuses, we did not observe such
an effect in metformin-exposed fetal liver (Figures 2d and e).
Instead, we observed an increase in G6pc expression
(Figure 2c). This discrepancy may arise from the different
nature of exposure (metformin versus HFD versus
dexamethasone).
Beyond its role as a gluconeogenesis regulator, HNF4α is
indispensable for morphological and functional development
of the liver. Loss of HNF4α not only blocks hepatocyte
differentiation but also affects hepatic architecture as well.
While some liver functions can be performed by all hepato-
cytes, other functions are limited to hepatocyte subsets.
Proper lobular organization and the position of hepatocytes
within the lobule are crucial for functional compartmentaliza-
tion, a phenomenon called positional (or zonal) heterogeneity
or metabolic zonation (reviewed in refs 25,33,34). It is thus
conceivable that altered hepatic Hnf4α expression during fetal
development as a result of gestational exposure to metformin,
to dexamethasone, or to maternal HFD could produce
profound effects on liver function, and hence whole-body
energy homeostasis later in life.
A previous study showed that treating dams on HFD before
and during gestation with metformin throughout pregnancy
protected offspring from developing glucose intolerance.19
However, this result was confounded by the fact that the study
used a mouse model that did not separate effects of maternal
diabetes from HFD, given that HFD in the absence of maternal
diabetes has been shown to induce T2D in the adult
offspring.31,32,35 Therefore, this mousemodel was not suitable
for studying metformin effects on offspring of mothers who
were treated with metformin for T2D or GDM during
pregnancy. While the regular-diet mouse model we used in
this report does not mimic the pregnant human patients
treated with metformin for T2D or GDM, it does provide a
cautionary note that metformin has the potential of directly
impacting the fetus by altering hepatic development and
function, irrespective of the conditions of the mother. Thus,
using metformin-like drugs that do not pass the placenta may
remove the potentially negative effects of metformin on the
offspring.
It was initially unexpected to observe that metformin
upregulates H19 expression both in mouse fetal livers
(Figure 2a) and in human Huh7 hepatoma cells (Figure 3d),
given that metformin inhibits H19 expression in human
endometrial and ovarian cancer cells.16,36 Metformin has also
long been known to repress gluconeogenesis in the adult
liver.37 However, this apparent contradiction could be
explained by cell/tissue-dependent and developmental
stage-dependent effects of metformin. It is intriguing to
observe a decreased expression of Insr in liver of metformin-
exposed fetuses (Figure 2f), a likely indirect effect of
metformin, as metformin did not alter Insr expression in
Huh7 cells (data not shown). Insulin signaling has been
implicated in liver enzymic differentiation in the fetus, as fetal
hyperinsulinemia was associated with reduced activity of
G6PC and PEPCK (reviewed in ref. 33). Although speculative,
the decreased Insr expression in the fetal liver might contribute
to increased expression of gluconeogenic genes. Finally, the
mechanism by which H19 is upregulated and Insr is down-
regulated by metformin in the fetal liver remains to be
investigated.
In summary, we propose a model illustrated in Figure 5. In
this model, gestational metformin exposure directly upregu-
lates H19 and indirectly downregulates Insr in the fetal liver.
H19 acts to decrease Hnf4α methylation, thereby increasing
Hnf4α expression, which drives premature gluconeogenic
gene expression; decreased insulin signaling also contributes
to this process. Increased Hnf4α expression also alters
hepatocyte differentiation. Together, they increase the risk of
metabolic disorders in adult life.
Materials and methods
Materials. Antibodies for G6PC (Abcam, Cambridge, MA, USA; ab83690; used
at a dilution of 1/500), HNF4α (Abcam, ab181604; used at a dilution of 1/1000),
Figure 5 A proposed model
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PEPCK (Abcam, ab70358; used at a dilution of 1/1000), and beta-actin (ACTB; Cell
Signaling, 4967; used at a dilution of 1/5000) were purchased. Plasmids expressing
human H19 (pH19) and empty vector (Vec) were previously described.27 Metformin
(ENZO Life Sciences International Inc., Uniondale, NY, USA; ALX-270-432-G005)
and DEA (Santa Cruz, Dallas, TX, USA; sc-207632) were purchased. DEA was
used at a final concentration of 20 μM.
Animals. All animal work was approved by the Yale University Institutional
Animal Care and Use Committee. CD-1 mice were obtained from Charles River
Laboratories (Wilmington, MA, USA). Mice were housed at 22–24 °C with a 12 h
light/12 h dark cycle with standard chow (Purina Chow; Purina Mills, Richmond, IN,
USA) and water provided ad libitum. Eight-week-old female mice were mated to
male mice. The morning of the detection of a vaginal plug was designated as E0.5.
Pregnant mice were then housed individually and metformin or control (tap water)
was administrated orally at 250 mg/kg from E0.5 through E18. On gestational day
18.5 (E18.5), pregnant dams were fasted for 6 h and then killed by standard carbon
dioxide inhalation before they underwent cesarean delivery to collect tissues from
dams and offspring. Fetal weights were recorded. Tissue samples were snap-frozen
in liquid nitrogen and stored at − 80 °C for further analysis. Blood samples were
collected by cardiac puncture from the dams in terminal anesthesia with
ISOTHESIA (isoflurane, Henry Schein Animal Health, Dublin, OH, USA). Serum
samples were used for blood glucose measurement using Bayer’s Breeze2 Blood
Glucose Monitoring System (Bayer, Leverkusen, Germany; 440C) according to the
manufacturer’s instructions.
Cell culture and transfection. Huh7 cells (ThermoFisher Scientific LLC,
Suwance, GA, USA; NC0377393) were authenticated and were free from
mycoplasma contamination. The cells were cultured in low-glucose DMEM (Gibco,
Grand Island, NY, USA; 11885-085) supplemented with 10% fetal bovine serum,
heat-inactivated, and 1% penicillin/streptomycin. Cells were transfected as
previously described.15,16 RNA, genomic DNA, and protein were extracted and
analyzed at the indicated time points following transfection.
Metformin treatment of Huh7 cells. Huh7 cells growing in 24-well plates
were incubated with metformin in growth medium at the indicated concentrations.
RNAs were extracted 48 h later and analyzed by RT-qPCR.
RNA extraction and RT-qPCR. Total RNA was extracted from fetal liver
tissue samples or from Huh7 cells using PureLink RNA Mini Kit (Ambion, Grand
Island, NY, USA; 12183018A). cDNA was synthesized using PrimeScript RT
Reagent Kit (Takara, Mountain View, CA, USA; RR037A) in a 20 μl reaction
containing 100–200 ng of total RNA. RT-qPCR was performed as previously
described.15,16 Gene expression levels were normalized against house-keeping
genes Hprt1 and Rpl0. The real-time PCR primers are listed below.
Mouse H19 forward: 5′-CCTCAAGATGAAAGAAATGGTGCTA-3′
Mouse H19 reverse: 5′-TCAGAACGAGACGGACTTAAAGAA-3′
Mouse Hnf4α forward: 5′-TCTTCTTTGATCCAGATGCC-3′
Mouse Hnf4α reverse: 5′-GGTCGTTGATGTAATCCTCC-3′
Mouse Insr forward: 5′-CCCCACCCTTTGAGTCTGAT-3′
Mouse Insr reverse: 5′-CTGTCACATTCCCCACCTCT-3′
Mouse G6pc forward: 5′-ATCCGGGGCATCTACAATG-3′
Mouse G6pc reverse: 5′-TGGCAAAGGGTGTAGTGTCA-3′
Mouse Pck1 forward: 5′-TGTTTACTGGGAAGGCATCG-3′
Mouse Pck1 reverse: 5′-AGGTCTACGGCCACCAAAG-3′
Mouse Pck2 forward: 5′-CCCTATCACAAGGCAAGAGA-3′
Mouse Pck2 reverse: 5′-CCACTTCCCCTGTCCTATTT-3′
Mouse Hprt1 forward: 5′-CAGTCCCAGCGTCGTGATTA-3′
Mouse Hprt1 reverse: 5′-GGCCTCCCATCTCCTTCATG-3′
Mouse Rpl0 forward: 5′-GATGGGCAACTGTACCTGACTG-3′
Mouse Rpl0 reverse: 5′-CTGGGCTCCTCTTGGAATG-3′
Mouse Igf2 forward: 5′-GCTTGTTGACACGCTTCAGTTTG-3′
Mouse Igf2 reverse: 5′-GTTGGCACGGCTTGAAGGC-3′
Human H19 forward: 5′-ACTCAGGAATCGGCTCTGGAA-3′
Human H19 reverse: 5′-CTGCTGTTCCGATGGTGTCTT-3′
Human Hnf4α forward: 5′-CAGAATGAGCGGGACCGGATC-3′
Human Hnf4α reverse: 5′-CAGCAGCTGCTCCTTCATGGAC-3′
Human Igf2 forward: 5′-CCGAAACAGGCTACTCTCCT-3′
Human Igf2 reverse: 5′-AGGGTGTTTAAAGCCAATCG-3′
Human G6pc forward: 5′-CCTCAGGAATGCCTTCTACG-3′
Human G6pc reverse: 5′-TCTCCAATCACAGCTACCCA-3′
Human Pck1 forward: 5′-GGTTCCCAGGGTGCATGAAA-3′
Human Pck1 reverse: 5′-CACGTAGGGTGAATCCGTCAG-3′
Human Prt1 forward: 5′-GACCAGTCAACAGGGGACAT-3′
Human Prt1 reverse: 5′-CCTGACCAAGGAAAGCAAAG-3′
Human Rpl0 forward: 5′-GGCGACCTGGAAGTCCAACT-3′
Human Rpl0 reverse: 5′-CCATCAGCACCACAGCCTTC-3′
Western blot analysis. Protein levels were determined by SDS-
polyacrylamide gel electrophoresis followed by blotting against their specific
antibodies as previously described.15,16
Glucose output assay. This was performed using Amplex Red Glucose/
Glucose Oxidase Assay Kit (A22189, Molecular Probes, Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s instructions. Briefly, Huh7 cells were
transfected with pH19 or Vec in a 24-well plate. Forty-eight hours later, culture
medium was replaced with glucose-free DMEM (Gibco; 11966-025) for 2 h and then
incubated in 120 μl glucose production media (glucose-free DMEM, 20 mM sodium
lactate, 2 mM sodium pyruvate, and 0.5% BSA) for 4 h. Subsequently, 50 μl of
supernatant was used for measurement of glucose concentration, which was
normalized to total protein content of cells.
Quantitative methylation-specific PCR. Genomic DNA was extracted
from fetal liver tissue samples or from Huh7 cells in one well of 24-well plates using
Quick-gDNA MicroPrep (Zymo Research Corporation, Irvine, CA, USA; D3021)
according to the manufacturer’s instructions. For bisulfite treatment, 400–500 ng of
DNA was used for each column using EZ DNA Methylation-Gold Kit (Zymo, D5006).
A volume of 100 μl of elution buffer was used to elute DNA from each column. RT-
qPCR was performed in a 15 μl reaction containing 5 μl of the eluant using
iQSYBRGreen in a Bio-Rad (Hercules, CA, USA) iCycler. The PCR primers for
methylated DNA were used at a final concentration of 0.3 μM in each PCR reaction.
PCR was performed by initial denaturation at 95 °C for 5 min, followed by 40 cycles
of 30 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. Ct values of each sample were
used in the post-PCR data analysis. Albumin DNA was used as loading controls for
QMSP normalization. The primers used for QMSP are listed below.
Human Hnf4αmethylated forward: 5′-TTTAATTTTAGAGTGTAGGATTAGGATTCG-3′
HumanHnf4αmethylated reverse: 5′-TCTTCTAATCACCCAAAATAAATAAATACG-3′
Human albumin forward: 5′-GTATGCCTGAGCCCCAAAGT-3′
Human albumin reverse: 5′-CCTTGGGCTTGTGTTTCACG-3′
Mouse Hnf4α methylated forward: 5′-GATTAGAAGAATTAATAAGATAATCGGGC-3′
Mouse Hnf4α methylated reverse: 5′-AAACAAAAACCCACACACAACAAC-3′
Mouse albumin forward: 5′-GTGAGAATTGTAGAGCAGTGCTGTC-3′
Mouse albumin reverse: 5′-ACATTGCTCAGCACAGATCCAC-3′
Statistical analysis. Statistical analyses were performed using the Statistical
Package for the Social Science (SPSS) computer software version 17.0 (IBM SPSS
Statistics, Chicago, IL, USA). In vivo gene expression data are presented as median
and interquartile range and analyzed using Mann–Whitney U-test. Spearman corre-
lations were performed for gene co-expression analyses. In vitro data are presented
as mean±S.D. and analyzed using two-tailed Student’s t-test. Figures were
constructed using Prism 6 version 6.0f (GraphPad Software, Inc., La Jolla, CA, USA).
P-values at 0.05 or smaller (two-sided) were considered statistically significant.
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